Lee A Meier1,2,3, Jennifer L Auger1,2, Brianna J Engelson1,3, Hannah M Cowan1, Elise R Breed4,3, Mayra I Gonzalez-Torres1,2,3, Joshua D Boyer5, Mayank Verma6,3, Aubyn Marath7, Bryce A Binstadt8,2,3. 1. Center for Immunology (L.A.M., J.L.A., B.J.E., H.M.C., M.I.G.-T., B.A.B.). 2. Department of Pediatrics (L.A.M., J.L.A., M.I.G.-T., B.A.B.). 3. University of Minnesota Medical School (L.A.M., B.J.E., E.R.B., M.I.G.-T., M.V., B.A.B.), Minneapolis. 4. Department of Laboratory Medicine and Pathology (E.R.B.). 5. Department of Medicine, University of California, San Diego (J.D.B.). 6. Department of Integrative Biology and Physiology (M.V.). 7. CardioStart International, Tampa, FL (A.M.). 8. Center for Immunology (L.A.M., J.L.A., B.J.E., H.M.C., M.I.G.-T., B.A.B.) binstadt@umn.edu.
Abstract
BACKGROUND: Valvular heart disease is common and affects the mitral valve (MV) most frequently. Despite the prevalence of MV disease (MVD), the cellular and molecular pathways that initiate and perpetuate it are not well understood. METHODS: K/B.g7 T-cell receptor transgenic mice spontaneously develop systemic autoantibody-associated autoimmunity, leading to fully penetrant fibroinflammatory MVD and arthritis. We used multiparameter flow cytometry, intracellular cytokine staining, and immunofluorescent staining to characterize the cells in inflamed K/B.g7 MVs. We used genetic approaches to study the contribution of mononuclear phagocytes (MNPs) to MVD in this model. Specifically, we generated K/B.g7 mice in which either CX3CR1 or CD301b/macrophage galactose N-acetylgalactosamine-specific lectin 2 (MGL2)-expressing MNPs were ablated. Using K/B.g7 mice expressing Cx3Cr1-Cre, we conditionally deleted critical inflammatory molecules from MNPs, including the Fc-receptor signal-transducing tyrosine kinase Syk and the cell adhesion molecule very late antigen-4. We performed complementary studies using monoclonal antibodies to block key inflammatory molecules. We generated bone marrow chimeric mice to define the origin of the inflammatory cells present in the MV and to determine which valve cells respond to the proinflammatory cytokine tumor necrosis factor (TNF). Finally, we examined specimens from patients with rheumatic heart disease to correlate our findings to human pathology. RESULTS: MNPs comprised the vast majority of MV-infiltrating cells; these MNPs expressed CX3CR1 and CD301b/MGL2. Analogous cells were present in human rheumatic heart disease valves. K/B.g7 mice lacking CX3CR1 or in which CD301b/MGL2-expressing MNPs were ablated were protected from MVD. The valve-infiltrating CD301b/MGL2+ MNPs expressed tissue-reparative molecules including arginase-1 and resistin-like molecule α. These MNPs also expressed the proinflammatory cytokines TNF and interleukin-6, and antibody blockade of these cytokines prevented MVD. Deleting Syk from CX3CR1-expressing MNPs reduced their TNF and interleukin-6 production and also prevented MVD. TNF acted through TNF receptor-1 expressed on valve-resident cells to increase the expression of vascular cell adhesion molecule-1. Conditionally deleting the vascular cell adhesion molecule-1 ligand very late antigen-4 from CX3CR1-expressing MNPs prevented MVD. CONCLUSIONS: CD301b/MGL2+ MNPs are key drivers of autoimmune MVD in K/B.g7 mice and are also present in human rheumatic heart disease. We define key inflammatory molecules that drive MVD in this model, including Syk, TNF, interleukin-6, very late antigen-4, and vascular cell adhesion molecule-1.
BACKGROUND:Valvular heart disease is common and affects the mitral valve (MV) most frequently. Despite the prevalence of MV disease (MVD), the cellular and molecular pathways that initiate and perpetuate it are not well understood. METHODS:K/B.g7 T-cell receptor transgenic mice spontaneously develop systemic autoantibody-associated autoimmunity, leading to fully penetrant fibroinflammatory MVD and arthritis. We used multiparameter flow cytometry, intracellular cytokine staining, and immunofluorescent staining to characterize the cells in inflamed K/B.g7 MVs. We used genetic approaches to study the contribution of mononuclear phagocytes (MNPs) to MVD in this model. Specifically, we generated K/B.g7mice in which either CX3CR1 or CD301b/macrophage galactose N-acetylgalactosamine-specific lectin 2 (MGL2)-expressing MNPs were ablated. Using K/B.g7mice expressing Cx3Cr1-Cre, we conditionally deleted critical inflammatory molecules from MNPs, including the Fc-receptor signal-transducing tyrosine kinase Syk and the cell adhesion molecule very late antigen-4. We performed complementary studies using monoclonal antibodies to block key inflammatory molecules. We generated bone marrow chimeric mice to define the origin of the inflammatory cells present in the MV and to determine which valve cells respond to the proinflammatory cytokine tumor necrosis factor (TNF). Finally, we examined specimens from patients with rheumatic heart disease to correlate our findings to human pathology. RESULTS: MNPs comprised the vast majority of MV-infiltrating cells; these MNPs expressed CX3CR1 and CD301b/MGL2. Analogous cells were present in humanrheumatic heart disease valves. K/B.g7mice lacking CX3CR1 or in which CD301b/MGL2-expressing MNPs were ablated were protected from MVD. The valve-infiltrating CD301b/MGL2+ MNPs expressed tissue-reparative molecules including arginase-1 and resistin-like molecule α. These MNPs also expressed the proinflammatory cytokines TNF and interleukin-6, and antibody blockade of these cytokines prevented MVD. Deleting Syk from CX3CR1-expressing MNPs reduced their TNF and interleukin-6 production and also prevented MVD. TNF acted through TNF receptor-1 expressed on valve-resident cells to increase the expression of vascular cell adhesion molecule-1. Conditionally deleting the vascular cell adhesion molecule-1 ligand very late antigen-4 from CX3CR1-expressing MNPs prevented MVD. CONCLUSIONS:CD301b/MGL2+ MNPs are key drivers of autoimmune MVD in K/B.g7mice and are also present in humanrheumatic heart disease. We define key inflammatory molecules that drive MVD in this model, including Syk, TNF, interleukin-6, very late antigen-4, and vascular cell adhesion molecule-1.
Authors: Simon Yona; Ki-Wook Kim; Yochai Wolf; Alexander Mildner; Diana Varol; Michal Breker; Dalit Strauss-Ayali; Sergey Viukov; Martin Guilliams; Alexander Misharin; David A Hume; Harris Perlman; Bernard Malissen; Elazar Zelzer; Steffen Jung Journal: Immunity Date: 2012-12-27 Impact factor: 31.745
Authors: Yosuke Kumamoto; Melissa Linehan; Jason S Weinstein; Brian J Laidlaw; Joseph E Craft; Akiko Iwasaki Journal: Immunity Date: 2013-09-26 Impact factor: 31.745
Authors: Maarten Hulsmans; Sebastian Clauss; Ling Xiao; Aaron D Aguirre; Kevin R King; Alan Hanley; William J Hucker; Eike M Wülfers; Gunnar Seemann; Gabriel Courties; Yoshiko Iwamoto; Yuan Sun; Andrej J Savol; Hendrik B Sager; Kory J Lavine; Gregory A Fishbein; Diane E Capen; Nicolas Da Silva; Lucile Miquerol; Hiroko Wakimoto; Christine E Seidman; Jonathan G Seidman; Ruslan I Sadreyev; Kamila Naxerova; Richard N Mitchell; Dennis Brown; Peter Libby; Ralph Weissleder; Filip K Swirski; Peter Kohl; Claudio Vinegoni; David J Milan; Patrick T Ellinor; Matthias Nahrendorf Journal: Cell Date: 2017-04-20 Impact factor: 41.582
Authors: Andrew J Kim; Na Xu; Kazuhiro Umeyama; Alexia Hulin; Sithara Raju Ponny; Ronald J Vagnozzi; Ellis A Green; Paul Hanson; Bruce M McManus; Hiroshi Nagashima; Katherine E Yutzey Journal: Circulation Date: 2020-01-13 Impact factor: 29.690
Authors: Lee A Meier; Jessica L Faragher; Victoria Osinski; Jennifer L Auger; Rochus Voeller; Aubyn Marath; Bryce A Binstadt Journal: J Immunol Date: 2022-06-03 Impact factor: 5.426